FDA clears Riverain's updated chest CAD technology
The FDA has granted approval for Riverain Medical’s newest version of the OnGuard chest x-ray computer-aided detection (CAD) technology.
OnGuard identifies solitary pulmonary nodules that may represent early-stage lung cancer on an existing chest x-ray, according to the Dayton, Ohio-based company. Because OnGuard utilizes the existing digital chest x-ray, Riverain added that there is no additional radiation dose, patient procedure, hardware or standalone workstation needed to integrate the CAD technology into a radiology department.
OnGuard identifies solitary pulmonary nodules that may represent early-stage lung cancer on an existing chest x-ray, according to the Dayton, Ohio-based company. Because OnGuard utilizes the existing digital chest x-ray, Riverain added that there is no additional radiation dose, patient procedure, hardware or standalone workstation needed to integrate the CAD technology into a radiology department.